Elan, Biogen change Tysabri label due to PML risk
DUBLIN, Nov 7 (Reuters) - Ireland's Elan (ELN.I: Quote, Profile, Research) and U.S. drugmaker Biogen Idec (BIIB.O: Quote, Profile, Research) have amended the label of their multiple sclerosis drug Tysabri to reflect the increased risk of contracting a potentially deadly brain infection, Elan said in a statement on Saturday.
Last month European regulators began a review of the drug following reports of 23 cases of progressive multifocal leukoencephalopathy, or PML. [ID:nnN23102944]
The label changes specified that the occurrence of PML in patients treated for 24 to 36 months is generally similar to the 1-in-1,000 rate seen in clinical trials, Elan said.
Tysabri was temporarily withdrawn from the market in 2005 after being linked with PML. It was reintroduced in July 2006 with stricter safety warnings.
Tysabri is considered the most important driver of growth for Elan and Biogen and shares in both companies fell sharply after the most recent PML cases were reported last month. (Reporting by Padraic Halpin; editing by Chris Pizzey)
© Thomson Reuters 2009 All rights reserved
India Investment Summit 2009
Top executives and bankers discuss their own plans and the broader opportunities and challenges for India during the Reuters India Investment Summit in Mumbai and Bangalore. Full Coverage | Blog
PLAYBOY SALE
An icon bows to changing times
With his Playboy Enterprises in talks to be sold for about $300 million, the 83 year-old Hugh Hefner will be giving up control over the iconic adult entertainment empire he founded that was instrumental in shaping society's opinions on nudity, sex and free speech. Full Article
India
US
UK
